<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">32202669</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>13</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>14</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1749-6632</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>1499</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Sep</Month>
            </PubDate>
          </JournalIssue>
          <Title>Annals of the New York Academy of Sciences</Title>
          <ISOAbbreviation>Ann N Y Acad Sci</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Myeloid cells in sepsis-acquired immunodeficiency.</ArticleTitle>
        <Pagination>
          <StartPage>3</StartPage>
          <EndPage>17</EndPage>
          <MedlinePgn>3-17</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1111/nyas.14333</ELocationID>
        <Abstract>
          <AbstractText>On May 2017, the World Health Organization recognized sepsis as a global health priority. Sepsis profoundly perturbs immune homeostasis by initiating a complex response that varies over time, with the concomitant occurrence of pro- and anti-inflammatory mechanisms. Sepsis deeply impacts myeloid cell response. Different mechanisms are at play, such as apoptosis, endotoxin tolerance, metabolic failure, epigenetic reprogramming, and central regulation. This induces systemic effects on circulating immune cells and impacts progenitors locally in lymphoid organs. In the bone marrow, a progressive shift toward the release of immature myeloid cells (including myeloid-derived suppressor cells), at the expense of mature neutrophils, takes place. Circulating dendritic cell number remains dramatically low and monocytes/macrophages display an anti-inflammatory phenotype and reduced antigen presentation capacity. Intensity and persistence of these alterations are associated with increased risk of deleterious outcomes in patients. Thus, myeloid cells dysfunctions play a prominent role in the occurrence of sepsis-acquired immunodeficiency. For the most immunosuppressed patients, this paves the way for clinical trials evaluating immunoadjuvant molecules (granulocyte-macrophage colony-stimulating factor and interferon gamma) aimed at restoring homeostatic myeloid cell response. Our review offers a summary of sepsis-induced myeloid cell dysfunctions and current therapeutic strategies proposed to target these defects in patients.</AbstractText>
          <CopyrightInformation>© 2020 New York Academy of Sciences.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Venet</LastName>
            <ForeName>Fabienne</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>EA 7426 Pathophysiology of Injury-Induced Immunosuppression (PI3), Claude Bernard University Lyon 1, Hospices Civils de Lyon, Lyon, France.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Immunology Laboratory, Hospices Civils de Lyon, Edouard Herriot Hospital, Lyon, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Demaret</LastName>
            <ForeName>Julie</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Institut d'Immunologie, Lille University and University Hospital (CHU), Lille, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gossez</LastName>
            <ForeName>Morgane</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>EA 7426 Pathophysiology of Injury-Induced Immunosuppression (PI3), Claude Bernard University Lyon 1, Hospices Civils de Lyon, Lyon, France.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Immunology Laboratory, Hospices Civils de Lyon, Edouard Herriot Hospital, Lyon, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Monneret</LastName>
            <ForeName>Guillaume</ForeName>
            <Initials>G</Initials>
            <Identifier Source="ORCID">0000-0002-9961-5739</Identifier>
            <AffiliationInfo>
              <Affiliation>EA 7426 Pathophysiology of Injury-Induced Immunosuppression (PI3), Claude Bernard University Lyon 1, Hospices Civils de Lyon, Lyon, France.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Immunology Laboratory, Hospices Civils de Lyon, Edouard Herriot Hospital, Lyon, France.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>03</Month>
          <Day>23</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Ann N Y Acad Sci</MedlineTA>
        <NlmUniqueID>7506858</NlmUniqueID>
        <ISSNLinking>0077-8923</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004198" MajorTopicYN="N">Disease Susceptibility</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016867" MajorTopicYN="N">Immunocompromised Host</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007153" MajorTopicYN="N">Immunologic Deficiency Syndromes</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D022423" MajorTopicYN="N">Myeloid Cells</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000072737" MajorTopicYN="N">Myeloid-Derived Suppressor Cells</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009928" MajorTopicYN="N">Organ Specificity</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018805" MajorTopicYN="N">Sepsis</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
          <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">HLA-DR</Keyword>
        <Keyword MajorTopicYN="Y">MDSC</Keyword>
        <Keyword MajorTopicYN="Y">immunodeficiency</Keyword>
        <Keyword MajorTopicYN="Y">immunosuppression</Keyword>
        <Keyword MajorTopicYN="Y">monocyte</Keyword>
        <Keyword MajorTopicYN="Y">myeloid</Keyword>
        <Keyword MajorTopicYN="Y">sepsis</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="revised">
          <Year>2020</Year>
          <Month>2</Month>
          <Day>25</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="received">
          <Year>2019</Year>
          <Month>12</Month>
          <Day>27</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>3</Month>
          <Day>4</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>3</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>3</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">32202669</ArticleId>
        <ArticleId IdType="doi">10.1111/nyas.14333</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Title>References</Title>
        <Reference>
          <Citation>Singer, M. et al. 2016. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 315: 801-810.</Citation>
        </Reference>
        <Reference>
          <Citation>Rhee, C. et al. 2017. Incidence and trends of sepsis in US hospitals using clinical vs claims data, 2009-2014. JAMA 318: 1241-1249.</Citation>
        </Reference>
        <Reference>
          <Citation>Fleischmann, C. et al. 2016. Assessment of global incidence and mortality of hospital-treated sepsis. Current estimates and limitations. Am. J. Respir. Crit. Care Med. 193: 259-272.</Citation>
        </Reference>
        <Reference>
          <Citation>Kaukonen, K.M., M. Bailey, S. Suzuki, et al. 2014. Mortality related to severe sepsis and septic shock among critically ill patients in Australia and New Zealand, 2000-2012. JAMA 311: 1308-1316.</Citation>
        </Reference>
        <Reference>
          <Citation>Rhodes, A. et al. 2017. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med. 43: 304-377.</Citation>
        </Reference>
        <Reference>
          <Citation>Blot, S. et al. 2019. Epidemiology of intra-abdominal infection and sepsis in critically ill patients: “AbSeS”, a multinational observational cohort study and ESICM Trials Group Project. Intensive Care Med. 45: 1703-1717.</Citation>
        </Reference>
        <Reference>
          <Citation>Gaieski, D.F., J.M. Edwards, M.J. Kallan &amp; B.G. Carr. 2013. Benchmarking the incidence and mortality of severe sepsis in the United States. Crit. Care Med. 41: 1167-1174.</Citation>
        </Reference>
        <Reference>
          <Citation>Liu, V. et al. 2014. Hospital deaths in patients with sepsis from 2 independent cohorts. JAMA 312: 90-92.</Citation>
        </Reference>
        <Reference>
          <Citation>Vincent, J.L. et al. 2014. Assessment of the worldwide burden of critical illness: the intensive care over nations (ICON) audit. Lancet Respir. Med. 2: 380-386.</Citation>
        </Reference>
        <Reference>
          <Citation>Angus, D.C. et al. 2001. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit. Care Med. 29: 1303-1310.</Citation>
        </Reference>
        <Reference>
          <Citation>Deutschman, C.S. &amp; K.J. Tracey. 2014. Sepsis: current dogma and new perspectives. Immunity 40: 463-475.</Citation>
        </Reference>
        <Reference>
          <Citation>Reinhart, K. et al. 2017. Recognizing sepsis as a global health priority-a WHO resolution. N. Engl. J. Med. 377: 414-417.</Citation>
        </Reference>
        <Reference>
          <Citation>van der Poll, T., F.L. van de Veerdonk, B.P. Scicluna &amp; M.G. Netea. 2017. The immunopathology of sepsis and potential therapeutic targets. Nat. Rev. Immunol. 17: 407-420.</Citation>
        </Reference>
        <Reference>
          <Citation>Hotchkiss, R.S., G. Monneret &amp; D. Payen. 2013. Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy. Nat. Rev. Immunol. 13: 862-874.</Citation>
        </Reference>
        <Reference>
          <Citation>Netea, M.G. et al. 2017. A guiding map for inflammation. Nat. Immunol. 18: 826-831.</Citation>
        </Reference>
        <Reference>
          <Citation>Peiseler, M. &amp; P. Kubes. 2018. Macrophages play an essential role in trauma-induced sterile inflammation and tissue repair. Eur. J. Trauma Emerg. Surg. 44: 335-349.</Citation>
        </Reference>
        <Reference>
          <Citation>Pradeu, T. &amp; E.L. Cooper. 2012. The danger theory: 20 years later. Front. Immunol. 3: 287.</Citation>
        </Reference>
        <Reference>
          <Citation>Nedeva, C., J. Menassa &amp; H. Puthalakath. 2019. Sepsis: inflammation is a necessary evil. Front. Cell Dev. Biol. 7: 108.</Citation>
        </Reference>
        <Reference>
          <Citation>Wiersinga, W.J., S.J. Leopold, D.R. Cranendonk &amp; T. van der Poll. 2014. Host innate immune responses to sepsis. Virulence 5: 36-44.</Citation>
        </Reference>
        <Reference>
          <Citation>Zeni, F., B. Freeman &amp; C. Natanson. 1997. Anti-inflammatory therapies to treat sepsis and septic shock: a reassessment. Crit. Care Med. 25: 1095-1100.</Citation>
        </Reference>
        <Reference>
          <Citation>Opal, S.M. 2014. The current understanding of sepsis and research priorities for the future. Virulence 5: 1-3.</Citation>
        </Reference>
        <Reference>
          <Citation>Bone, R.C., C.J. Grodzin &amp; R.A. Balk. 1997. Sepsis: a new hypothesis for pathogenesis of the disease process. Chest 112: 235-243.</Citation>
        </Reference>
        <Reference>
          <Citation>Hotchkiss, R.S., G. Monneret &amp; D. Payen. 2013. Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach. Lancet Infect. Dis. 13: 260-268.</Citation>
        </Reference>
        <Reference>
          <Citation>Otto, G.P. et al. 2011. The late phase of sepsis is characterized by an increased microbiological burden and death rate. Crit. Care 15: R183.</Citation>
        </Reference>
        <Reference>
          <Citation>Torgersen, C. et al. 2009. Macroscopic postmortem findings in 235 surgical intensive care patients with sepsis. Anesth. Analg. 108: 1841-1847.</Citation>
        </Reference>
        <Reference>
          <Citation>van Vught, L.A. et al. 2016. Incidence, risk factors, and attributable mortality of secondary infections in the intensive care unit after admission for sepsis. JAMA 315: 1469-1479.</Citation>
        </Reference>
        <Reference>
          <Citation>Chavan, S.S. &amp; K.J. Tracey. 2017. Essential neuroscience in immunology. J. Immunol. 198: 3389-3397.</Citation>
        </Reference>
        <Reference>
          <Citation>Sternberg, E.M. 2006. Neural regulation of innate immunity: a coordinated nonspecific host response to pathogens. Nat. Rev. Immunol. 6: 318-328.</Citation>
        </Reference>
        <Reference>
          <Citation>Stolk, R.F. et al. 2016. Potentially inadvertent immunomodulation: norepinephrine use in sepsis. Am. J. Respir. Crit. Care Med. 194: 550-558.</Citation>
        </Reference>
        <Reference>
          <Citation>Hotchkiss, R.S. et al. 2000. Rapid onset of intestinal epithelial and lymphocyte apoptotic cell death in patients with trauma and shock. Crit. Care Med. 28: 3207-3217.</Citation>
        </Reference>
        <Reference>
          <Citation>Hotchkiss, R.S. et al. 2001. Sepsis-induced apoptosis causes progressive profound depletion of B and CD4+ T lymphocytes in humans. J. Immunol. 166: 6952-6963.</Citation>
        </Reference>
        <Reference>
          <Citation>Boomer, J.S. et al. 2011. Immunosuppression in patients who die of sepsis and multiple organ failure. JAMA 306: 2594-2605.</Citation>
        </Reference>
        <Reference>
          <Citation>Hotchkiss, R.S. &amp; D.W. Nicholson. 2006. Apoptosis and caspases regulate death and inflammation in sepsis. Nat. Rev. Immunol. 6: 813-822.</Citation>
        </Reference>
        <Reference>
          <Citation>Hotchkiss, R.S. et al. 2003. Adoptive transfer of apoptotic splenocytes worsens survival, whereas adoptive transfer of necrotic splenocytes improves survival in sepsis. Proc. Natl. Acad. Sci. USA 100: 6724-6729.</Citation>
        </Reference>
        <Reference>
          <Citation>Seeley, J.J. &amp; S. Ghosh. 2017. Molecular mechanisms of innate memory and tolerance to LPS. J. Leukoc. Biol. 101: 107-119.</Citation>
        </Reference>
        <Reference>
          <Citation>Biswas, S.K. &amp; E. Lopez-Collazo. 2009. Endotoxin tolerance: new mechanisms, molecules and clinical significance. Trends Immunol. 30: 475-487.</Citation>
        </Reference>
        <Reference>
          <Citation>Liu, D., S. Cao, Y. Zhou, et al. 2019. Recent advances in endotoxin tolerance. J. Cell. Biochem. 120: 56-70.</Citation>
        </Reference>
        <Reference>
          <Citation>Wolk, K., W.D. Docke, V. von Baehr, et al. 2000. Impaired antigen presentation by human monocytes during endotoxin tolerance. Blood 96: 218-223.</Citation>
        </Reference>
        <Reference>
          <Citation>Shalova, I.N. et al. 2015. Human monocytes undergo functional re-programming during sepsis mediated by hypoxia-inducible factor-1α. Immunity 42: 484-498.</Citation>
        </Reference>
        <Reference>
          <Citation>Allantaz-Frager, F. et al. 2013. Identification of biomarkers of response to IFNg during endotoxin tolerance: application to septic shock. PLoS One 8: e68218.</Citation>
        </Reference>
        <Reference>
          <Citation>van ’t Veer, C. et al. 2007. Induction of IRAK-M is associated with lipopolysaccharide tolerance in a human endotoxemia model. J. Immunol. 179: 7110-7120.</Citation>
        </Reference>
        <Reference>
          <Citation>Novakovic, B. et al. 2016. β-Glucan reverses the epigenetic state of LPS-induced immunological tolerance. Cell 167: 1354-1368.e1314.</Citation>
        </Reference>
        <Reference>
          <Citation>Netea, M.G. et al. 2016. Trained immunity: a program of innate immune memory in health and disease. Science 352: aaf1098.</Citation>
        </Reference>
        <Reference>
          <Citation>McCall, C.E., M. El Gazzar, T. Liu, et al. 2011. Epigenetics, bioenergetics, and microRNA coordinate gene-specific reprogramming during acute systemic inflammation. J. Leukoc. Biol. 90: 439-446.</Citation>
        </Reference>
        <Reference>
          <Citation>McCall, C.E. &amp; B.K. Yoza. 2007. Gene silencing in severe systemic inflammation. Am. J. Respir. Crit. Care Med. 175: 763-767.</Citation>
        </Reference>
        <Reference>
          <Citation>Netea, M.G. 2019. Hard to remember: long-term functional defects in myeloid cells and wound repair after sepsis. Arterioscler. Thromb. Vasc. Biol. 39: 2205-2206.</Citation>
        </Reference>
        <Reference>
          <Citation>Dominguez-Andres, J. &amp; M.G. Netea. 2019. Long-term reprogramming of the innate immune system. J. Leukoc. Biol. 105: 329-338.</Citation>
        </Reference>
        <Reference>
          <Citation>Carson, W.F., K.A. Cavassani, Y. Dou &amp; S.L. Kunkel. 2011. Epigenetic regulation of immune cell functions during post-septic immunosuppression. Epigenetics 6: 273-283.</Citation>
        </Reference>
        <Reference>
          <Citation>Davenport, E.E. et al. 2016. Genomic landscape of the individual host response and outcomes in sepsis: a prospective cohort study. Lancet Respir. Med. 4: 259-271.</Citation>
        </Reference>
        <Reference>
          <Citation>Venet, F. &amp; G. Monneret. 2018. Advances in the understanding and treatment of sepsis-induced immunosuppression. Nat. Rev. Nephrol. 14: 121-137.</Citation>
        </Reference>
        <Reference>
          <Citation>Zhang, Q. &amp; X. Cao. 2019. Epigenetic regulation of the innate immune response to infection. Nat. Rev. Immunol. 19: 417-432.</Citation>
        </Reference>
        <Reference>
          <Citation>Arora, H. et al. 2019. The ATP-binding cassette gene ABCF1 functions as an E2 ubiquitin-conjugating enzyme controlling macrophage polarization to dampen lethal septic shock. Immunity 50: 418-431.e416.</Citation>
        </Reference>
        <Reference>
          <Citation>Cheng, S.C. et al. 2014. mTOR- and HIF-1α-mediated aerobic glycolysis as metabolic basis for trained immunity. Science 345: 1250684.</Citation>
        </Reference>
        <Reference>
          <Citation>Arts, R.J., M.S. Gresnigt, L.A. Joosten &amp; M.G. Netea. 2017. Cellular metabolism of myeloid cells in sepsis. J. Leukoc. Biol. 101: 151-164.</Citation>
        </Reference>
        <Reference>
          <Citation>O'Neill, L.A., R.J. Kishton &amp; J. Rathmell. 2016. A guide to immunometabolism for immunologists. Nat. Rev. Immunol. 16: 553-565.</Citation>
        </Reference>
        <Reference>
          <Citation>Arts, R.J. et al. 2016. Glutaminolysis and fumarate accumulation integrate immunometabolic and epigenetic programs in trained immunity. Cell Metab. 24: 807-819.</Citation>
        </Reference>
        <Reference>
          <Citation>Cheng, S.C. et al. 2016. Broad defects in the energy metabolism of leukocytes underlie immunoparalysis in sepsis. Nat. Immunol. 17: 406-413.</Citation>
        </Reference>
        <Reference>
          <Citation>Endo, A., M. Okamura, S. Yoshikawa, et al. 2017. Multilateral functional alterations of human neutrophils in sepsis: from the point of diagnosis to the seventh day. Shock 48: 629-637.</Citation>
        </Reference>
        <Reference>
          <Citation>Denning, N.L., M. Aziz, S.D. Gurien &amp; P. Wang. 2019. DAMPs and NETs in sepsis. Front. Immunol. 10: 2536.</Citation>
        </Reference>
        <Reference>
          <Citation>Fialkow, L. et al. 2006. Neutrophil apoptosis: a marker of disease severity in sepsis and sepsis-induced acute respiratory distress syndrome. Crit. Care 10: R155.</Citation>
        </Reference>
        <Reference>
          <Citation>Kovach, M.A. &amp; T.J. Standiford. 2012. The function of neutrophils in sepsis. Curr. Opin. Infect. Dis. 25: 321-327.</Citation>
        </Reference>
        <Reference>
          <Citation>Pillay, J. et al. 2012. A subset of neutrophils in human systemic inflammation inhibits T cell responses through Mac-1. J. Clin. Invest. 122: 327-336.</Citation>
        </Reference>
        <Reference>
          <Citation>Demaret, J. et al. 2015. Marked alterations of neutrophil functions during sepsis-induced immunosuppression. J. Leukoc. Biol. 98: 1081-1090.</Citation>
        </Reference>
        <Reference>
          <Citation>Hampson, P. et al. 2017. Neutrophil dysfunction, immature granulocytes, and cell-free DNA are early biomarkers of sepsis in burn-injured patients: a prospective observational cohort study. Ann. Surg. 265: 1241-1249.</Citation>
        </Reference>
        <Reference>
          <Citation>Drifte, G., I. Dunn-Siegrist, P. Tissieres &amp; J. Pugin. 2013. Innate immune functions of immature neutrophils in patients with sepsis and severe systemic inflammatory response syndrome. Crit. Care Med. 41: 820-832.</Citation>
        </Reference>
        <Reference>
          <Citation>Guerin, E. et al. 2014. Circulating immature granulocytes with T cell killing functions predict sepsis deterioration. Crit. Care Med. 42: 2007-2018.</Citation>
        </Reference>
        <Reference>
          <Citation>Huang, X. et al. 2014. Identification of B7-H1 as a novel mediator of the innate immune/proinflammatory response as well as a possible myeloid cell prognostic biomarker in sepsis. J. Immunol. 192: 1091-1099.</Citation>
        </Reference>
        <Reference>
          <Citation>Wang, J.F. et al. 2015. Up-regulation of programmed cell death 1 ligand 1 on neutrophils may be involved in sepsis-induced immunosuppression: an animal study and a prospective case-control study. Anesthesiology 122: 852-863.</Citation>
        </Reference>
        <Reference>
          <Citation>Patera, A.C. et al. 2016. Frontline Science: defects in immune function in patients with sepsis are associated with PD-1 or PD-L1 expression and can be restored by antibodies targeting PD-1 or PD-L1. J. Leukoc. Biol. 100: 1239-1254.</Citation>
        </Reference>
        <Reference>
          <Citation>Kasten, K.R., J.T. Muenzer &amp; C.C. Caldwell. 2010. Neutrophils are significant producers of IL-10 during sepsis. Biochem. Biophys. Res. Commun. 393: 28-31.</Citation>
        </Reference>
        <Reference>
          <Citation>van der Meer, A.J. et al. 2019. Neutrophils mitigate the systemic host response during endotoxemia in mice. Immunology 156: 277-281.</Citation>
        </Reference>
        <Reference>
          <Citation>Gresnigt, M.S. et al. 2012. Neutrophil-mediated inhibition of proinflammatory cytokine responses. J. Immunol. 189: 4806-4815.</Citation>
        </Reference>
        <Reference>
          <Citation>Huang, X., F. Venet, C.S. Chung, et al. 2007. Changes in dendritic cell function in the immune response to sepsis. Cell- &amp; tissue-based therapy. Expert Opin. Biol. Ther. 7: 929-938.</Citation>
        </Reference>
        <Reference>
          <Citation>Hotchkiss, R.S. et al. 2002. Depletion of dendritic cells, but not macrophages, in patients with sepsis. J. Immunol. 168: 2493-2500.</Citation>
        </Reference>
        <Reference>
          <Citation>Guisset, O. et al. 2007. Decrease in circulating dendritic cells predicts fatal outcome in septic shock. Intensive Care Med. 33: 148-152.</Citation>
        </Reference>
        <Reference>
          <Citation>D'Arpa, N. et al. 2009. Circulating dendritic cells following burn. Burns 35: 513-518.</Citation>
        </Reference>
        <Reference>
          <Citation>Riccardi, F. et al. 2011. Flow cytometric analysis of peripheral blood dendritic cells in patients with severe sepsis. Cytometry B Clin. Cytom. 80: 14-21.</Citation>
        </Reference>
        <Reference>
          <Citation>Dreschler, K. et al. 2012. Altered phenotype of blood dendritic cells in patients with acute pneumonia. Respiration 83: 209-217.</Citation>
        </Reference>
        <Reference>
          <Citation>Grimaldi, D. et al. 2011. Profound and persistent decrease of circulating dendritic cells is associated with ICU-acquired infection in patients with septic shock. Intensive Care Med. 37: 1438-1446.</Citation>
        </Reference>
        <Reference>
          <Citation>Pasquevich, K.A. et al. 2015. Innate immune system favors emergency monopoiesis at the expense of DC-differentiation to control systemic bacterial infection in mice. Eur. J. Immunol. 45: 2821-2833.</Citation>
        </Reference>
        <Reference>
          <Citation>Bouras, M., K. Asehnoune &amp; A. Roquilly. 2018. Contribution of dendritic cell responses to sepsis-induced immunosuppression and to susceptibility to secondary pneumonia. Front. Immunol. 9: 2590.</Citation>
        </Reference>
        <Reference>
          <Citation>Poulin, L.F., C. Lasseaux &amp; M. Chamaillard. 2018. Understanding the cellular origin of the mononuclear phagocyte system sheds light on the myeloid postulate of immune paralysis in sepsis. Front. Immunol. 9: 823.</Citation>
        </Reference>
        <Reference>
          <Citation>Faivre, V. et al. 2012. Human monocytes differentiate into dendritic cells subsets that induce anergic and regulatory T cells in sepsis. PLoS One 7: e47209.</Citation>
        </Reference>
        <Reference>
          <Citation>Faivre, V. et al. 2007. Accelerated in vitro differentiation of blood monocytes into dendritic cells in human sepsis. Clin. Exp. Immunol. 147: 426-439.</Citation>
        </Reference>
        <Reference>
          <Citation>Roquilly, A. et al. 2017. Local modulation of antigen-presenting cell development after resolution of pneumonia induces long-term susceptibility to secondary infections. Immunity 47: 135-147.e135.</Citation>
        </Reference>
        <Reference>
          <Citation>Roquilly, A. et al. 2013. TLR-4 agonist in post-haemorrhage pneumonia: role of dendritic and natural killer cells. Eur. Respir. J. 42: 1365-1378.</Citation>
        </Reference>
        <Reference>
          <Citation>Roquilly, A. et al. 2010. CpG-ODN and MPLA prevent mortality in a murine model of post-hemorrhage-Staphyloccocus aureus pneumonia. PLoS One 5: e13228.</Citation>
        </Reference>
        <Reference>
          <Citation>Roquilly, A. &amp; J.A. Villadangos. 2015. The role of dendritic cell alterations in susceptibility to hospital-acquired infections during critical-illness related immunosuppression. Mol. Immunol. 68: 120-123.</Citation>
        </Reference>
        <Reference>
          <Citation>Wen, H., Y. Dou, C.M. Hogaboam &amp; S.L. Kunkel. 2008. Epigenetic regulation of dendritic cell-derived interleukin-12 facilitates immunosuppression after a severe innate immune response. Blood 111: 1797-1804.</Citation>
        </Reference>
        <Reference>
          <Citation>Wen, H., M.A. Schaller, Y. Dou, et al. 2008. Dendritic cells at the interface of innate and acquired immunity: the role for epigenetic changes. J. Leukoc. Biol. 83: 439-446.</Citation>
        </Reference>
        <Reference>
          <Citation>Wang, H.W. et al. 2012. Treatment with Fms-like tyrosine kinase 3 ligand reverses lung dendritic cell immunoparalysis and ameliorates zymosan-induced secondary lung injury in mice. Clin. Exp. Immunol. 170: 156-166.</Citation>
        </Reference>
        <Reference>
          <Citation>Gautier, E.L. et al. 2008. Enhanced dendritic cell survival attenuates lipopolysaccharide-induced immunosuppression and increases resistance to lethal endotoxic shock. J. Immunol. 180: 6941-6946.</Citation>
        </Reference>
        <Reference>
          <Citation>Pene, F. et al. 2008. Dendritic cells modulate lung response to Pseudomonas aeruginosa in a murine model of sepsis-induced immune dysfunction. J. Immunol. 181: 8513-8520.</Citation>
        </Reference>
        <Reference>
          <Citation>Bohannon, J. et al. 2008. Prophylactic treatment with fms-like tyrosine kinase-3 ligand after burn injury enhances global immune responses to infection. J. Immunol. 180: 3038-3048.</Citation>
        </Reference>
        <Reference>
          <Citation>Toliver-Kinsky, T.E., W. Cui, E.D. Murphey, et al. 2005. Enhancement of dendritic cell production by fms-like tyrosine kinase-3 ligand increases the resistance of mice to a burn wound infection. J. Immunol. 174: 404-410.</Citation>
        </Reference>
        <Reference>
          <Citation>Pastille, E. et al. 2011. Modulation of dendritic cell differentiation in the bone marrow mediates sustained immunosuppression after polymicrobial sepsis. J. Immunol. 186: 977-986.</Citation>
        </Reference>
        <Reference>
          <Citation>Benjamim, C.F., S.K. Lundy, N.W. Lukacs, et al. 2005. Reversal of long-term sepsis-induced immunosuppression by dendritic cells. Blood 105: 3588-3595.</Citation>
        </Reference>
        <Reference>
          <Citation>Vega-Ramos, J., A. Roquilly, K. Asehnoune &amp; J.A. Villadangos. 2014. Modulation of dendritic cell antigen presentation by pathogens, tissue damage and secondary inflammatory signals. Curr. Opin. Pharmacol. 17: 64-70.</Citation>
        </Reference>
        <Reference>
          <Citation>Cavaillon, J.M. &amp; M. Adib-Conquy. 2006. Bench-to-bedside review: endotoxin tolerance as a model of leukocyte reprogramming in sepsis. Crit. Care 10: 233.</Citation>
        </Reference>
        <Reference>
          <Citation>Gordon, S. 2003. Alternative activation of macrophages. Nat. Rev. Immunol. 3: 23-35.</Citation>
        </Reference>
        <Reference>
          <Citation>Simpson, S.Q., H.N. Modi, R.A. Balk, et al. 1991. Reduced alveolar macrophage production of tumor necrosis factor during sepsis in mice and men. Crit. Care Med. 19: 1060-1066.</Citation>
        </Reference>
        <Reference>
          <Citation>Reddy, R.C. et al. 2001. Alveolar macrophage deactivation in murine septic peritonitis: role of interleukin 10. Infect. Immun. 69: 1394-1401.</Citation>
        </Reference>
        <Reference>
          <Citation>Muehlstedt, S.G., M. Lyte &amp; J.L. Rodriguez. 2002. Increased IL-10 production and HLA-DR suppression in the lungs of injured patients precede the development of nosocomial pneumonia. Shock 17: 443-450.</Citation>
        </Reference>
        <Reference>
          <Citation>Chalk, K. et al. 2013. Dysfunction of alveolar macrophages after cardiac surgery and postoperative pneumonia?-an observational study. Crit. Care 17: R285.</Citation>
        </Reference>
        <Reference>
          <Citation>Astiz, M., D. Saha, D. Lustbader, et al. 1996. Monocyte response to bacterial toxins, expression of cell surface receptors, and release of anti-inflammatory cytokines during sepsis. J. Lab. Clin. Med. 128: 594-600.</Citation>
        </Reference>
        <Reference>
          <Citation>Nierhaus, A. et al. 2003. Reversal of immunoparalysis by recombinant human granulocyte-macrophage colony-stimulating factor in patients with severe sepsis. Intensive Care Med. 29: 646-651.</Citation>
        </Reference>
        <Reference>
          <Citation>Piani, A. et al. 2000. Expression of MHC class II molecules contributes to lipopolysaccharide responsiveness. Eur. J. Immunol. 30: 3140-3146.</Citation>
        </Reference>
        <Reference>
          <Citation>Monneret, G., F. Venet, A. Pachot &amp; A. Lepape. 2008. Monitoring immune dysfunctions in the septic patient: a new skin for the old ceremony. Mol. Med. 14: 64-78.</Citation>
        </Reference>
        <Reference>
          <Citation>Venet, F., A.C. Lukaszewicz, D. Payen, et al. 2013. Monitoring the immune response in sepsis: a rational approach to administration of immunoadjuvant therapies. Curr. Opin. Immunol. 25: 477-483.</Citation>
        </Reference>
        <Reference>
          <Citation>Galbraith, N., S. Walker, J. Carter &amp; H.C. Polk, Jr. 2016. Past, present, and future of augmentation of monocyte function in the surgical patient. Surg. Infect. (Larchmt) 17: 563-569.</Citation>
        </Reference>
        <Reference>
          <Citation>Galbraith, N., S. Walker, S. Galandiuk, et al. 2016. The significance and challenges of monocyte impairment: for the ill patient and the surgeon. Surg. Infect. (Larchmt) 17: 303-312.</Citation>
        </Reference>
        <Reference>
          <Citation>Dimitrov, E., E. Enchev, G. Minkov, et al. 2020. Poor outcome could be predicted by lower monocyte human leukocyte antigen-DR expression in patients with complicated intra-abdominal infections: a review. Surg. Infect. (Larchmt) 21: 77-80.</Citation>
        </Reference>
        <Reference>
          <Citation>Monneret, G. &amp; F. Venet. 2015. Sepsis-induced immune alterations monitoring by flow cytometry as a promising tool for individualized therapy. Cytometry B Clin. Cytom. 90: 376-386.</Citation>
        </Reference>
        <Reference>
          <Citation>Monneret, G. et al. 2006. Persisting low monocyte human leukocyte antigen-DR expression predicts mortality in septic shock. Intensive Care Med. 32: 1175-1183.</Citation>
        </Reference>
        <Reference>
          <Citation>Landelle, C. et al. 2010. Low monocyte human leukocyte antigen-DR is independently associated with nosocomial infections after septic shock. Intensive Care Med. 36: 1859-1866.</Citation>
        </Reference>
        <Reference>
          <Citation>Lorente-Sorolla, C. et al. 2019. Inflammatory cytokines and organ dysfunction associate with the aberrant DNA methylome of monocytes in sepsis. Genome Med. 11: 66.</Citation>
        </Reference>
        <Reference>
          <Citation>Davis, F.M. et al. 2019. Sepsis induces prolonged epigenetic modifications in bone marrow and peripheral macrophages impairing inflammation and wound healing. Arterioscler. Thromb. Vasc. Biol. 39: 2353-2366.</Citation>
        </Reference>
        <Reference>
          <Citation>Mengos, A.E., D.A. Gastineau &amp; M.P. Gustafson. 2019. The CD14+HLA-DRlo/neg monocyte: an immunosuppressive phenotype that restrains responses to cancer immunotherapy. Front. Immunol. 10: 1147.</Citation>
        </Reference>
        <Reference>
          <Citation>Hotchkiss, R.S. &amp; L.L. Moldawer. 2014. Parallels between cancer and infectious disease. N. Engl. J. Med. 371: 380-383.</Citation>
        </Reference>
        <Reference>
          <Citation>Schrijver, I.T., C. Theroude &amp; T. Roger. 2019. Myeloid-derived suppressor cells in sepsis. Front. Immunol. 10: 327.</Citation>
        </Reference>
        <Reference>
          <Citation>Gabrilovich, D.I. &amp; S. Nagaraj. 2009. Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 9: 162-174.</Citation>
        </Reference>
        <Reference>
          <Citation>Veglia, F., M. Perego &amp; D. Gabrilovich. 2018. Myeloid-derived suppressor cells coming of age. Nat. Immunol. 19: 108-119.</Citation>
        </Reference>
        <Reference>
          <Citation>Ost, M. et al. 2016. Myeloid-derived suppressor cells in bacterial infections. Front. Cell. Infect. Microbiol. 6: 37.</Citation>
        </Reference>
        <Reference>
          <Citation>Dorhoi, A. &amp; N. Du Plessis. 2018. Monocytic myeloid-derived suppressor cells in chronic infections. Front. Immunol. 8: 1895.</Citation>
        </Reference>
        <Reference>
          <Citation>Dai, J., A. Kumbhare, D. Youssef, et al. 2017. Intracellular S100A9 promotes myeloid-derived suppressor cells during late sepsis. Front. Immunol. 8: 1565.</Citation>
        </Reference>
        <Reference>
          <Citation>Llitjos, J.F. et al. 2016. Sepsis-induced expansion of granulocytic myeloid-derived suppressor cells promotes tumour growth through Toll-like receptor 4. J. Pathol. 239: 473-483.</Citation>
        </Reference>
        <Reference>
          <Citation>McPeak, M.B. et al. 2017. Myeloid cell-specific knockout of NFI-A improves sepsis survival. Infect. Immun. 85: 4.</Citation>
        </Reference>
        <Reference>
          <Citation>McPeak, M.B. et al. 2017. Frontline Science: myeloid cell-specific deletion of Cebpb decreases sepsis-induced immunosuppression in mice. J. Leukoc. Biol. 102: 191-200.</Citation>
        </Reference>
        <Reference>
          <Citation>Landoni, V.I. et al. 2016. Immature myeloid Gr-1+ CD11b+ cells from lipopolysaccharide-immunosuppressed mice acquire inhibitory activity in the bone marrow and migrate to lymph nodes to exert their suppressive function. Clin. Sci. (Lond.) 130: 259-271.</Citation>
        </Reference>
        <Reference>
          <Citation>Ren, D. et al. 2012. Myeloid-derived suppressor cells accumulate in the liver site after sepsis to induce immunosuppression. Cell. Immunol. 279: 12-20.</Citation>
        </Reference>
        <Reference>
          <Citation>Janols, H. et al. 2014. A high frequency of MDSCs in sepsis patients, with the granulocytic subtype dominating in gram-positive cases. J. Leukoc. Biol. 96: 685-693.</Citation>
        </Reference>
        <Reference>
          <Citation>Mathias, B. et al. 2016. Human myeloid-derived suppressor cells are associated with chronic immune suppression after severe sepsis/septic shock. Ann. Surg. 265: 827-834.</Citation>
        </Reference>
        <Reference>
          <Citation>Uhel, F. et al. 2017. Early expansion of circulating granulocytic myeloid-derived suppressor cells predicts development of nosocomial infections in patients with sepsis. Am. J. Respir. Crit. Care Med. 196: 315-327.</Citation>
        </Reference>
        <Reference>
          <Citation>Hollen, M.K. et al. 2019. Myeloid-derived suppressor cell function and epigenetic expression evolves over time after surgical sepsis. Crit. Care 23: 355.</Citation>
        </Reference>
        <Reference>
          <Citation>Mira, J.C. et al. 2017. Sepsis pathophysiology, chronic critical illness, and persistent inflammation-immunosuppression and catabolism syndrome. Crit. Care Med. 45: 253-262.</Citation>
        </Reference>
        <Reference>
          <Citation>Brudecki, L., D.A. Ferguson, C.E. McCall &amp; M. El Gazzar. 2012. Myeloid-derived suppressor cells evolve during sepsis and can enhance or attenuate the systemic inflammatory response. Infect. Immun. 80: 2026-2034.</Citation>
        </Reference>
        <Reference>
          <Citation>Bronte, V. et al. 2016. Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat. Commun. 7: 12150.</Citation>
        </Reference>
        <Reference>
          <Citation>Fleming, V. et al. 2018. Targeting myeloid-derived suppressor cells to bypass tumor-induced immunosuppression. Front. Immunol. 9: 398.</Citation>
        </Reference>
        <Reference>
          <Citation>Rubio, I. et al. 2019. Current gaps in sepsis immunology: new opportunities for translational research. Lancet Infect. Dis. 19: e422-e436.</Citation>
        </Reference>
        <Reference>
          <Citation>Delano, M.J. &amp; P.A. Ward. 2016. Sepsis-induced immune dysfunction: can immune therapies reduce mortality? J. Clin. Invest. 126: 23-31.</Citation>
        </Reference>
        <Reference>
          <Citation>Pickkers, P. &amp; M. Kox. 2017. Towards precision medicine for sepsis patients. Crit. Care 21: 11.</Citation>
        </Reference>
        <Reference>
          <Citation>Stanski, N.L. &amp; H.R. Wong. 2020. Prognostic and predictive enrichment in sepsis. Nat. Rev. Nephrol. 16: 20-31.</Citation>
        </Reference>
        <Reference>
          <Citation>Conway Morris, A. et al. 2018. Cell-surface signatures of immune dysfunction risk-stratify critically ill patients: INFECT study. Intensive Care Med. 44: 627-635.</Citation>
        </Reference>
        <Reference>
          <Citation>Payen, D. et al. 2019. Multicentric experience with interferon gamma therapy in sepsis induced immunosuppression. A case series. BMC Infect. Dis. 19: 931.</Citation>
        </Reference>
        <Reference>
          <Citation>Leentjens, J. et al. 2012. Reversal of immunoparalysis in humans in vivo: a double-blind, placebo-controlled, randomized pilot study. Am. J. Respir. Crit. Care Med. 186: 838-845.</Citation>
        </Reference>
        <Reference>
          <Citation>Docke, W.D. et al. 1997. Monocyte deactivation in septic patients: restoration by IFN-gamma treatment. Nat. Med. 3: 678-681.</Citation>
        </Reference>
        <Reference>
          <Citation>Nakos, G. et al. 2002. Immunoparalysis in patients with severe trauma and the effect of inhaled interferon-gamma. Crit. Care Med. 30: 1488-1494.</Citation>
        </Reference>
        <Reference>
          <Citation>Nalos, M. et al. 2012. Immune effects of interferon gamma in persistent staphylococcal sepsis. Am. J. Respir. Crit. Care Med. 185: 110-112.</Citation>
        </Reference>
        <Reference>
          <Citation>Lukaszewicz, A.C. et al. 2009. Monocytic HLA-DR expression in intensive care patients: interest for prognosis and secondary infection prediction. Crit. Care Med. 37: 2746-2752.</Citation>
        </Reference>
        <Reference>
          <Citation>Delsing, C.E. et al. 2014. Interferon-gamma as adjunctive immunotherapy for invasive fungal infections: a case series. BMC Infect. Dis. 14: 166.</Citation>
        </Reference>
        <Reference>
          <Citation>Cutino-Moguel, M.T., C. Eades, K. Rezvani &amp; D. Armstrong-James. 2017. Immunotherapy for infectious diseases in haematological immunocompromise. Br. J. Haematol. 177: 348-356.</Citation>
        </Reference>
        <Reference>
          <Citation>Grimaldi, D., O. Pradier, R.S. Hotchkiss &amp; J.L. Vincent. 2017. Nivolumab plus interferon-γ in the treatment of intractable mucormycosis. Lancet Infect. Dis. 17: 18.</Citation>
        </Reference>
        <Reference>
          <Citation>Hall, M.W. et al. 2011. Immunoparalysis and nosocomial infection in children with multiple organ dysfunction syndrome. Intensive Care Med. 37: 525-532.</Citation>
        </Reference>
        <Reference>
          <Citation>Nelson, L.A. 2007. Use of granulocyte-macrophage colony-stimulating factor to reverse anergy in otherwise immunologically healthy children. Ann. Allergy Asthma Immunol. 98: 373-382.</Citation>
        </Reference>
        <Reference>
          <Citation>Drossou-Agakidou, V. et al. 2002. In vivo effect of rhGM-CSF and rhG-CSF on monocyte HLA-DR expression of septic neonates. Cytokine 18: 260-265.</Citation>
        </Reference>
        <Reference>
          <Citation>Protti, A. et al. 2014. Granulocyte-macrophage colony stimulating factor for non-resolving legionellosis. Anaesth. Intensive Care 42: 804-806.</Citation>
        </Reference>
        <Reference>
          <Citation>Meisel, C. et al. 2009. Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial. Am. J. Respir. Crit. Care Med. 180: 640-648.</Citation>
        </Reference>
        <Reference>
          <Citation>Mathias, B., B.E. Szpila, F.A. Moore, et al. 2015. A review of GM-CSF therapy in sepsis. Medicine (Baltimore) 94: e2044.</Citation>
        </Reference>
        <Reference>
          <Citation>Dyck, L. &amp; K.H.G. Mills. 2017. Immune checkpoints and their inhibition in cancer and infectious diseases. Eur. J. Immunol. 47: 765-779.</Citation>
        </Reference>
        <Reference>
          <Citation>Shekarian, T. et al. 2017. Pattern recognition receptors: immune targets to enhance cancer immunotherapy. Ann. Oncol. 28: 1756-1766.</Citation>
        </Reference>
        <Reference>
          <Citation>Davis, C.G. et al. 2013. TLR3 agonist improves survival to secondary pneumonia in a double injury model. J. Surg. Res. 182: 270-276.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
